share_log

ATE.TO: Plans on Track for Acute Pain Program for Otenaproxesul...

ATE.TO: Plans on Track for Acute Pain Program for Otenaproxesul...

ATE.TO:奥替那普索的急性疼痛计划正在进行中。
Benzinga Real-time News ·  2022/09/12 12:05
By David Bautz, PhD
作者:David Bautz博士
OTC:ATBPF | TSX:ATE.TO
场外交易:ATBPF|多伦多证交所:ATE.TO
READ THE FULL ATE.TO RESEARCH REPORT
阅读完整的ATE研究报告
Business Update
商业动态
Phase 2 Post-Operative Pain Program to Initiate in Calendar 4Q22
第二阶段术后疼痛计划将于22季度日历启动
Antibe Therapeutics, Inc. (OTC:ATBPF) (TSX:ATE) is developing otenaproxesul as a solution to the dose-related gastrointestinal (GI) side effects associated with non-steroidal anti-inflammatory drugs (NSAIDs). It uses naproxen as a base molecule with a hydrogen sulfide moiety covalently attached. Hydrogen sulfide (H2S) is an important gasotransmitter, which is a gas that serves as an important signaling molecule in the body.
安替比治疗公司(场外交易代码:ATBPF)(多伦多证券交易所市场代码:ATE)正在开发一种治疗非类固醇抗炎药(NSAIDs)引起的与剂量相关的胃肠道(GI)副作用的解决方案。它使用萘普生作为碱基分子,与硫化氢部分共价连接。硫化氢(H)2S)是一种重要的气体传递器,它是一种气体,在人体内充当重要的信号分子。
The company is developing otenaproxesul for the management of acute...
该公司正在开发用于治...
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发